Literature DB >> 20347738

Primary hyperparathyroidism from parathyroid microadenoma: specific features and implications for a surgical strategy in the era of minimally invasive parathyroidectomy.

Nicolas Goasguen1, Mircea Chirica, Natacha Roger, Nicolas Munoz-Bongrand, Sarah Zohar, Severine Noullet, Anne de Roquancourt, Pierre Cattan, Emile Sarfati.   

Abstract

BACKGROUND: The aim of this study was to identify the specific preoperative characteristics of patients with parathyroid microadenoma and to report their outcomes after surgical treatment. STUDY
DESIGN: Parathyroid microadenomas (weight < 100 mg) were identified in 62 (6%) of the 1,012 patients operated on for a parathyroid adenoma between 1995 and 2004. Presentation and outcomes after surgery were compared with those of 124 patients operated on consecutively for parathyroid adenoma (>100 mg) during the last year of the study. All patients underwent bilateral surgical exploration of the neck. Success was defined as resection of a pathologic gland combined with normocalcemia at 6 months after operation. Logistic regression was used to test the relationship between groups and potential predictive factors of microadenoma.
RESULTS: There were 57 women (92%) and the median age was 57 years (range 29 to 77 years). Median preoperative calcemia and parathyroid hormone (PTH) serum levels were 2.64 mmol/L (range 2.31 to 3 mmol/L) and 79 pg/mL (range 30 to 189 pg/mL), respectively. There was no difference in the clinical presentation between patients with microadenoma and adenoma. Preoperative calcium (p < 0.001) and PTH serum levels (p = 0.014) were significantly higher in patients with adenoma. Calcium and PTH serum levels lower than 2.6 mmol/L and 60 pg/mL, respectively, predicted the presence of microadenoma with respective specificities of 0.89 and 0.87. Success rates were similar in the microadenoma and adenoma groups (92% vs 98%; p = 0.11).
CONCLUSIONS: Mild preoperative elevations of calcium or PTH serum levels should warn about the risk of microadenoma. In this setting, intraoperative difficulties should be expected in identifying the pathologic gland, and bilateral neck exploration should be the preferred surgical approach. Copyright (c) 2010 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20347738     DOI: 10.1016/j.jamcollsurg.2009.12.017

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  5 in total

1.  The small abnormal parathyroid gland is increasingly common and heralds operative complexity.

Authors:  Kelly L McCoy; Naomi H Chen; Michaele J Armstrong; Gina M Howell; Michael T Stang; Linwah Yip; Sally E Carty
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

Review 2.  Surgical treatment of primary hyperparathyroidism: description of techniques and advances in the field.

Authors:  Muhammad Adil Abbas Khan; Sadia Rafiq; Sophocles Lanitis; Farhan Arshad Mirza; Lukasz Gwozdziewicz; Ragheed Al-Mufti; Dimitri J Hadjiminas
Journal:  Indian J Surg       Date:  2013-04-21       Impact factor: 0.656

Review 3.  Overview of the 2022 WHO Classification of Parathyroid Tumors.

Authors:  Lori A Erickson; Ozgur Mete; C Christofer Juhlin; Aurel Perren; Anthony J Gill
Journal:  Endocr Pathol       Date:  2022-02-17       Impact factor: 3.943

Review 4.  Outcomes of Parathyroidectomy in Patients with Primary Hyperparathyroidism: A Systematic Review and Meta-analysis.

Authors:  Naykky M Singh Ospina; Rene Rodriguez-Gutierrez; Spyridoula Maraka; Ana E Espinosa de Ycaza; Sina Jasim; Ana Castaneda-Guarderas; Michael R Gionfriddo; Alaa Al Nofal; Juan P Brito; Patricia Erwin; Melanie Richards; Robert Wermers; Victor M Montori
Journal:  World J Surg       Date:  2016-10       Impact factor: 3.352

5.  Multigland disease and slower decline in intraoperative PTH characterize mild primary hyperparathyroidism.

Authors:  David F Schneider; Jocelyn F Burke; Kristin A Ojomo; Nicholas Clark; Haggi Mazeh; Rebecca S Sippel; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2013-08-14       Impact factor: 5.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.